Molecular Devices has introduced three new assay kits using its proprietary IMAP technology, two of them incorporating kinase enzymes from Upstate Biotechnology
Molecular Devices's proprietary Imap technology is a versatile assay format for kinase activity because it does not use specific antibodies.
Imap can be applied to almost any kinase as a mix-and-read assay.
It is robust, non-radioactive and miniaturised to minimise per-well cost in high throughput screening.
By including purified enzyme preparations from Upstate Biotechnology, the SGK and Akt assay kits provide complete systems for screening kinase inhibitors.
"Protein kinases have become a major target for research in cardiovascular disease, inflammation and the development of rationally-designed cancer drugs," stated Stephen Oldfield, vice president of worldwide marketing at Molecular Devices.
"Using Imap technology, we can screen inhibitors of almost any kinase in a high-throughput assay.
The SGK and Akt assays are the first in a series of more than ten kits being jointly developed with Upstate Biotechnology." Molecular Devices' installed base of family instruments in drug discovery laboratories worldwide is expected to provide a substantial platform for high-throughput screening using Imap technology.
